AIMSPRO in Established Diffuse Cutaneous Systemic Sclerosis

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2011 by Daval International Limited.
Recruitment status was  Active, not recruiting
Information provided by:
Daval International Limited Identifier:
First received: October 7, 2008
Last updated: August 16, 2011
Last verified: August 2011
To study the safety and tolerability of a hyperimmune goat serum product (AIMSPRO) in the treatment of systemic sclerosis (SSc) through a period of 26 weeks of study participation. The secondary objective of the study is to assess the efficacy of AIMSPRO as a therapeutic agent for SSc using inter alia the SSc-HAQ questionnaire and the modified Rodnan skin score.

Condition Intervention Phase
Systemic Sclerosis
Drug: Hyperimmune caprine serum
Drug: Albumin
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-Blind Placebo-Controlled Pilot Study of Safety and Tolerability of AIMSPRO in Established Diffuse Cutaneous Systemic Sclerosis

Resource links provided by NLM:

Further study details as provided by Daval International Limited:

Primary Outcome Measures:
  • Modified Rodnan Skin Score [ Time Frame: Baseline, Week 6 and Week 26 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Scleroderma Health Assessment Questionnaire [ Time Frame: Baseline, Week 6 and Week 26 ] [ Designated as safety issue: No ]
  • Scleroderma UK Functional Score [ Time Frame: Baseline, Week 6 and Week 26 ] [ Designated as safety issue: No ]
  • Patient and Physician Global Assessment (VAS) [ Time Frame: Baseline, Week 6 and Week 26 ] [ Designated as safety issue: No ]
  • SF-36 (Short form 36) [ Time Frame: Baseline, Week 6 and Week 26 ] [ Designated as safety issue: No ]
  • MRC Sum Score [ Time Frame: Week 0, Week 6 and Week 26 ] [ Designated as safety issue: No ]

Estimated Enrollment: 20
Study Start Date: December 2008
Estimated Study Completion Date: September 2011
Primary Completion Date: February 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: AIMSPRO Drug: Hyperimmune caprine serum
Subcutaneous injection of serum, 1ml twice weekly for 6 months
Other Names:
  • Ceremben
  • Hyperimmune goat serum
Placebo Comparator: Placebo Drug: Albumin
Subcutaneous injection of albumin, 1ml twice weekly for 6 months
Other Name: Placebo

  Show Detailed Description


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Must fulfill 1980 Preliminary Classification Criteria for systemic sclerosis of the American Rheumatism Association
  • Diffuse cutaneous SSc, as evidenced by skin sclerosis proximal to the elbows or knees and absence of the anti-centromere autoantibody
  • At least three years must have elapsed since the first non-Raynaud's manifestation
  • Men and women of childbearing potential must use adequate birth control measures for the duration of the study and should continue such precautions for six months after receiving the last injection of AIMSPRO.
  • Screening laboratory test results:

Hemoglobin > 8.5 g/dL WBC > 3.5 x 10^9/L Neutrophils > 1.5 x 10^9/L Platelets > 100 x 10^9/L SGOT (AST) and alkaline phosphatase levels must be within twice the upper limit of normal range for the laboratory conducting the test.

  • Patient must be able to adhere to the study visit schedule and other protocol requirements
  • Patient must be capable of giving informed consent and the consent must be obtained prior to any screening procedures
  • No radiological evidence of malignancy, infection or (previous) tuberculosis in a chest radiograph performed within three months prior to the first injection of study drug

Exclusion Criteria:

  • Women who are pregnant, nursing, or planning pregnancy within one and a half years after screening (i.e., approximately six months following last injection of study drug).
  • Use of any investigational drug within one month prior to screening or within five half-lives of the investigational agent, whichever is longer.
  • Use of a putative disease modifying drug (potential immunosuppressive drug) within one month of screening.
  • Treatment with any therapeutic agent targeted at reducing TNF (e.g., infliximab, pentoxifylline, thalidomide, etanercept, etc.) within three months of screening.
  • Previous administration of AIMSPRO.
  • History of known allergy to animal proteins.
  • Serious infections (such as pneumonia or pyelonephritis) in the previous three months. Less serious infections (such as acute upper respiratory tract infection [colds] or simple urinary tract infection) should be monitored to their conclusion or treated, as appropriate, prior to inclusion.
  • Active hepatitis-B or hepatitis-C.
  • Active tuberculosis.
  • Patients with opportunistic infections, including but not limited to evidence of active cytomegalovirus, active Pneumocystis carinii, Aspergillosis, histoplasmosis or atypical mycobacterium infection, etc, within the previous six months.
  • History of lymphoproliferative disease including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy of unusual size or location (such as nodes in the posterior triangle of the neck, infra-clavicular, epitrochlear, or periaortic areas), or splenomegaly.
  • Known recent substance abuse (drug or alcohol).
  • Poor tolerability of venepuncture or lack of adequate venous access for required blood sampling during the study period.
  • Presence of a transplanted organ (with the exception of a corneal transplant > three months prior to screening).
  • Patients receiving immunosuppressive therapy within one month of screening.
  • Patients with malignancy within the past five years.
  • Signs or symptoms of severe, progressive or uncontrolled renal, hepatic, haematologic, gastrointestinal, endocrine, pulmonary, cardiac or neurological disease (including demyelinating diseases such as multiple sclerosis).
  • Patients who, within the past three months, have had either a myocardial infarction, uncontrolled congestive cardiac failure, unstable angina, uncontrolled systemic hypotension or uncontrolled systemic hypertension.
  • Patients who have screening laboratory values which deviate 20% or more from the upper or lower limits of normal or which are considered to be clinically significant to the investigator.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00769028

United Kingdom
Centre for Rheumatology and Connective Tissue Diseases, Lower Ground Floor, Royal Free Hospital NHS Trust, Hampstead
London, United Kingdom, NW3 2QG
Sponsors and Collaborators
Daval International Limited
Principal Investigator: Christopher P Denton, PhD FRCP Royal Free Hospital NHS Trust
  More Information

No publications provided by Daval International Limited

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Prof. Christopher Denton, Royal Free Hospital NHS Trust Identifier: NCT00769028     History of Changes
Other Study ID Numbers: DISS01
Study First Received: October 7, 2008
Last Updated: August 16, 2011
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by Daval International Limited:
Systemic sclerosis
Diffuse cutaneous systemic sclerosis
Hyperimmune caprine serum
Goat Serum

Additional relevant MeSH terms:
Scleroderma, Diffuse
Scleroderma, Systemic
Connective Tissue Diseases
Pathologic Processes
Skin Diseases processed this record on November 27, 2015